13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • GO39942

    Acronym: 

    POLARIX

    ACTRN/NCT /ethics: 

    NCT03274492

    Scientific title: 

    A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (POLARIX)

    Summary of trial and patient characteristics

    Cancer Type Lymphoma
    Trial Type Treatment
    Phase Phase III Tumour Stream Lymphoma
    Age Range 18 years and older Cancer Stage
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Lymphoma
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Lymphoma
    Cancer Stage
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A phase 3, multi-center, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of Polatuzumab Vedotin in combination with Rituximab and CHP (R-CHP) versus Rituximab and CHOP (R-CHOP) in previously untreated patients with diffuse large B-Cell Lymphoma

    Lay Summary

    A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (POLARIX)

    Sponsor / Cooperative group

    Hoffmann-La Roche

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    The Queen Elizabeth Hospital Sue Yeend Sue.Yeend@sa.gov.au 08 8222 6148 U Hahn Recruiting
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Recruiting